NM32-2668
- Generic Name
- NM32-2668
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Triple Negative Breast CancerOvarian CarcinomaLeiomyosarcomaAdenocarcinoma - Gastroesophageal Junction (GEJ)Endometrial CancerPeritoneal CarcinomaMesothelioma, MalignantAdenocarcinoma of the StomachMelanoma, MalignantRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Numab Therapeutics AG
- Target Recruit Count
- 180
- Registration Number
- NCT06299163
- Locations
- 🇺🇸
Medical University of South Carolina (MUSC), Charleston, South Carolina, United States
🇺🇸The University of Chicago Medical Center (UCMC), Chicago, Illinois, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath